Navigation Links
Pharsight Achieves $7.4 Million in Quarterly Revenue
Date:1/24/2008

eriods. Pharsight believes the use of these non-GAAP financial measures provides an additional tool for investors to use in comparing its financial measures with other companies in Pharsight's industry, many of which present similar non-GAAP financial measures to investors. As noted, the non-GAAP financial measures discussed above exclude the effects of non-cash stock-based compensation expense and/or a non-cash accounting charge associated with the preferred stock conversion in the first quarter of fiscal 2008. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measure as detailed below.

Safe Harbor

This press release includes forward-looking statements, including statements regarding revenue, gross margin, the demand and market for our products and services, other growth strategies and opportunities, and our expectations for revenue and revenue growth, gross margin, net income, diluted earnings per share and annual cash flow for the fiscal year ending March 31, 2008. These forward-looking statements involve risks and uncertainties, and factors that could cause actual results to differ materially include the following: changes in the demand for Pharsight's products and services; changes in Pharsight's operating strategies, pricing models or research and development focus; the failure to develop new products and services or to keep pace with technological changes; the failure of the market for Pharsight's products and services to develop as expected; the failure to generate additional sales from existing customers or to generate sales to new customers; the failure to meet customers' expectations; uncertainties involved in pharmaceutical drug development; and changes in government regulation of the pharmaceutical industry. Fur
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
2. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
3. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
4. Pharsight Announces 1-For-3 Reverse Stock Split
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
7. Pharsight Hosts Fourth Annual PKS User Group Meeting
8. Pharsight Expands Strategic Consulting Services Team
9. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
10. Pharsight Achieves First License Sale for Public-Source Database
11. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... and MUMBAI, India , June ... NSE: TCS) a leading global IT services, consulting and ... as a Leader in Worldwide Life Sciences R&D Risk-Based ... " IDC MarketScape: Worldwide Life Science R&D Risk-Based Monitoring ... The report evaluated eight leading IT services ...
(Date:6/26/2015)... ... June 26, 2015 , ... DNA Genotek, ... of OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that it has awarded grants ... Gut Microbiome Grant Program. The company has awarded its OMNIgene®•GUT fecal/stool ...
(Date:6/25/2015)... June 25, 2015 Last June, a dedicated global ... the virus using large-scale genome sequencing. Their research, which was ... in the journal Cell (Park 2015) , ... over seven months of the recent Ebola outbreak. ... draft, data, workflows, and full edit history of the paper ...
(Date:6/25/2015)... ... June 25, 2015 , ... ... for its 2015 National Patient and Family Conference, Providing and Pursuing Answers: Advances ... the Renaissance Chicago O’Hare Suites Hotel, July 24-25, 2015. , “As advances in ...
Breaking Biology Technology:TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 3Open Science Takes Major Leap Forward 2Nationally Recognized Brain Tumor Experts to Speak at American Brain Tumor Association Patient and Family Conference 2
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... Development and InnovationMOUNTAIN VIEW, Calif., April 22 ... Pharmaceuticals & Biotechnology group assesses a variety of ... in cancer treatment. Physicians, nurses and patients ... reconstitution, home vs. office administration parameters, and barriers ...
... 22 GeneGo, Inc., a leading provider of software ... , today announced that the University of Cardiff has ... researchers will have access to GeneGo,s MetaCore, training and ... their partner relationship with GeneGo to provide a pathway ...
Cached Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... Jos Zanchetta, a member of the IOF Board and ... has been named the recipient of the prestigious Pierre ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ... growth of the Foundation and osteoporosis advocacy worldwide. ...
... the damage caused by a heart attack survived in the ... a mouse model, researchers at The University of Texas MD ... Circulation Research . The study, with researchers at the ... imaging techniques developed by researchers at MD Anderson to track ...
... a 1600 km-wide ash cloud over the Atlantic. The ... visible in stark contrast to white clouds framing this ... emitting steam and ash on 20 March, wreaking havoc ... week caused some flights to be suspended to and ...
Cached Biology News:Transplanted adult stem cells provide lasting help to injured hearts 2Transplanted adult stem cells provide lasting help to injured hearts 3Transplanted adult stem cells provide lasting help to injured hearts 4
...
cysteine and glycine-rich protein 2,...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
HSPBP1 Antibody...
Biology Products: